Skip to main content
H.R. 1525 119th Congress House

Protecting Life from Chemical Abortions Act

Official title: To prohibit the use or declaration of a public health emergency with respect to abortion, and for other purposes.

Introduced: February 24, 2025 Introduced by: Kevin Hern Republican · Oklahoma See on congress.gov
Health AbortionDrug safety, medical device, and laboratory regulationDrug therapyGovernment information and archives
More subjectsShow fewer subjects
Health information and medical recordsPrescription drugs
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 24, 2025
Referred to the House Committee on Energy and Commerce.
Feb 24, 2025
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now February 24, 2025

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Protecting Life from Chemical Abortions Act

This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)

The FDA regulates mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.

In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be program-certified in order to dispense mifepristone. The modifications allow certified retail pharmacies to dispense mifepristone pursuant to prescriptions that are written by certified prescribers.

The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention.

The bill also generally prohibits the declaration of a public health emergency with respect to abortions.

 

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Lobbying activity 5

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 1525: Protecting Life from Chemical Abortions Act. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1525/
MLA
"H.R. 1525: Protecting Life from Chemical Abortions Act." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1525/.
Bluebook (legal)
H.R. 1525, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1525/.
Markdown link
[H.R. 1525: Protecting Life from Chemical Abortions Act](https://openamerica.io/bill/119-HR-1525/)
Report a problem